BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24240137)

  • 21. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
    Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Choi SH; Park SW; Seong J
    Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.
    Kittaka H; Takahashi H; Ohigashi H; Gotoh K; Yamada T; Tomita Y; Hasegawa Y; Yano M; Ishikawa O
    World J Surg; 2013 Jan; 37(1):169-78. PubMed ID: 22955953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of MRI and 18F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer.
    Cho YB; Chun HK; Kim MJ; Choi JY; Park CM; Kim BT; Lee SJ; Yun SH; Kim HC; Lee WY
    World J Surg; 2009 Dec; 33(12):2688-94. PubMed ID: 19823904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
    J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients.
    Incerti E; Vanoli EG; Broggi S; Gumina C; Passoni P; Slim N; Fiorino C; Reni M; Mapelli P; Cattaneo M; Zanon S; Calandrino R; Gianolli L; Di Muzio N; Picchio M
    Nucl Med Commun; 2019 Oct; 40(10):1072-1080. PubMed ID: 31365502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.
    Li XX; Liu NB; Zhu L; Yuan XK; Yang CW; Ren P; Gong LL; Zhao LJ; Xu WG; Wang P
    Br J Radiol; 2015 Jul; 88(1051):20140590. PubMed ID: 25939819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy.
    Zhang A; Ren S; Yuan Y; Li X; Zhu X; Jiang L; Li D; Zuo C
    Medicine (Baltimore); 2019 Mar; 98(13):e15064. PubMed ID: 30921238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer: A Randomized Clinical Trial.
    Elit LM; Fyles AW; Gu CS; Pond GR; D'Souza D; Samant R; Anthes M; Thomas G; Filion M; Arsenault J; Dayes I; Whelan TJ; Gulenchyn KY; Metser U; Dhamanaskar K; Levine MN
    JAMA Netw Open; 2018 Sep; 1(5):e182081. PubMed ID: 30646153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
    Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
    Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
    Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
    J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
    Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
    Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer.
    Jakobsen JK; Frahm Nielsen T; Ipsen P; Albrecht-Beste E; Cardoso Costa J; Alslev L; Predbjørn Krarup K; Grønkaer Toft B; Høyer S; Bouchelouche K; Bjerggaard Jensen J
    BJU Int; 2021 Feb; 127(2):254-262. PubMed ID: 33448605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.